Document is current
Any future updates will be listed below
-
Authors
Reynolds, Richard J. https://orcid.org/0000-0001-6419-7779
Irvin, M. Ryan
Bridges, S. Louis
Kim, Hwasoon https://orcid.org/0000-0002-0561-3186
Merriman, Tony R. https://orcid.org/0000-0003-0844-8726
Arnett, Donna K. https://orcid.org/0000-0003-2219-657X
Singh, Jasvinder A.
Sumpter, Nicholas A.
Lupi, Alexa S.
Vazquez, Ana I. https://orcid.org/0000-0001-6618-7486
- License Information
-
More Information
Article History
Received: 25 February 2020
Revised: 6 December 2020
Accepted: 10 February 2021
First Online: 26 February 2021
Compliance with ethical standards
:
: AIV has received consultant fees from University of Alabama at Birmingham and University of Texas, Austin. JAS has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio health, Medscape, WebMD, Clinical Care options, Clearview healthcare partners, Putnam associates, Spherix, Practice Point communications, the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS is on the speaker’s bureau of Simply Speaking. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 12 companies. JAS serves on the FDA Arthritis Advisory Committee. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS previously served as a member of the following committees: member, the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee.
